Management of corneal vascularization

M Chaudhary. Nepal J Ophthalmol. 2011 Jul-Dec.

. 2011 Jul-Dec;3(2):218-9.

doi: 10.3126/nepjoph.v3i2.5284.

No abstract available

Similar articles

Bevacizumab in ophthalmology: the controversy moves forward.
Gillies MC. Gillies MC. Clin Exp Ophthalmol. 2010 May;38(4):333-4. doi: 10.1111/j.1442-9071.2010.02300.x. Clin Exp Ophthalmol. 2010. PMID: 20642588 No abstract available.
[Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].
Pérez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, Fernández-Sánchez L, Cuenca-Navarro N. Pérez-Santonja JJ, et al. Arch Soc Esp Oftalmol. 2013 Dec;88(12):473-81. doi: 10.1016/j.oftal.2013.07.007. Epub 2013 Oct 7. Arch Soc Esp Oftalmol. 2013. PMID: 24257257 Spanish.
Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery.
Gerten G. Gerten G. Cornea. 2008 Dec;27(10):1195-9. doi: 10.1097/ICO.0b013e318180e50f. Cornea. 2008. PMID: 19034142
Anti-VEGF therapy with bevacizumab for anterior segment eye disease.
Hosseini H, Nowroozzadeh MH, Salouti R, Nejabat M. Hosseini H, et al. Cornea. 2012 Mar;31(3):322-34. doi: 10.1097/ICO.0b013e31822480f9. Cornea. 2012. PMID: 22157572 Review.
Anterior segment uses of bevacizumab.
Bahar I, Yeung SN, Sella R, Slomovic A. Bahar I, et al. Curr Opin Ophthalmol. 2012 Jul;23(4):303-16. doi: 10.1097/ICU.0b013e3283548459. Curr Opin Ophthalmol. 2012. PMID: 22634640 Review.